Cargando…

Targeting EGFR and PI3K pathways in ovarian cancer

BACKGROUND: The epidermal growth factor receptor (EGFR) is expressed in ovarian cancer, but agents targeting this pathway have shown little effect as single agents. This may be due to the presence of alternative pathways, particularly activation of the PI3K/Akt/MTOR pathway. METHODS: We have therefo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glaysher, S, Bolton, L M, Johnson, P, Atkey, N, Dyson, M, Torrance, C, Cree, I A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790180/ https://www.ncbi.nlm.nih.gov/pubmed/24022196 http://dx.doi.org/10.1038/bjc.2013.529

Ejemplares similares

Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model
por: Glaysher, Sharon, et al.
Publicado: (2014)

Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways
por: Nabeshima, A, et al.
Publicado: (2015)

α-TEA cooperates with MEK or mTOR inhibitors to induce apoptosis via targeting IRS/PI3K pathways
por: Tiwary, R, et al.
Publicado: (2011)

Activation of the PI3K/AKT pathway correlates with prognosis in stage II colon cancer
por: Malinowsky, K, et al.
Publicado: (2014)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target
por: Iida, K, et al.
Publicado: (2011)

Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-κB signalling pathway and prognostic significance in prostate cancer
por: Koumakpayi, I H, et al.
Publicado: (2010)

The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer
por: Trinh, X B, et al.
Publicado: (2009)

Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells
por: Comamala, M, et al.
Publicado: (2011)

Laminin-332 promotes the invasion of oesophageal squamous cell carcinoma via PI3K activation
por: Baba, Y, et al.
Publicado: (2008)

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients
por: Ruiz, M I Galleges, et al.
Publicado: (2009)

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?
por: Paliga, A, et al.
Publicado: (2012)

PI3K/Akt signalling is required for the attachment and spreading, and growth in vivo of metastatic scirrhous gastric carcinoma
por: Matsuoka, T, et al.
Publicado: (2012)

Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1–PI3K–Rac1 pathway
por: Kamura, S, et al.
Publicado: (2010)

Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas
por: Colomiere, M, et al.
Publicado: (2009)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands
por: Lujan, B, et al.
Publicado: (2010)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis
por: de Graeff, P, et al.
Publicado: (2009)

EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer
por: Ålgars, A, et al.
Publicado: (2011)

Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status
por: Rego, R L, et al.
Publicado: (2010)

Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer
por: Pichler, M, et al.
Publicado: (2012)

Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer
por: Leffers, N, et al.
Publicado: (2010)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer
por: de Graeff, P, et al.
Publicado: (2008)

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
por: Modjtahedi, H, et al.
Publicado: (2012)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma
por: Keller, J, et al.
Publicado: (2013)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma
por: Kobayashi, M, et al.
Publicado: (2012)

Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
por: Mead, R, et al.
Publicado: (2011)

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75
por: Ryan, M C, et al.
Publicado: (2010)

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients
por: Scartozzi, M, et al.
Publicado: (2011)

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway
por: Pils, D, et al.
Publicado: (2007)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions
por: Terry, G, et al.
Publicado: (2007)

An immunohistochemical perspective of PPARβ and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours
por: Ahmed, N, et al.
Publicado: (2008)

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
por: O'Brien, P M, et al.
Publicado: (2008)

Protein shedding in urothelial bladder cancer: prognostic implications of soluble urinary EGFR and EpCAM
por: Bryan, R T, et al.
Publicado: (2015)

Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy
por: Zlobec, I, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_rlcbmlbockog5qco3nscvocrk6